mmol/l) and' restricted oral fluids. Parenteral hydrocortisone therapy was given, replaced after 48 hours by oral prednisone.
On Days 6-8 of her inpatient admission she received Synacthen Depot I mg i.m. daily. After clinical improvement for seven days she became psychotic and paranoid over the next two days. She then improved considerably but remained apprehensive and uncooperative, limiting further investigations. She went home on the 18th day taking thyroxine 0.1 mg daily and prednisone 2.5 mg three times a day. Further investigations: Pituitary tomography, EEG and ECG normal. Reiter protein complement fixation text and VDRL negative. Antinuclear factor negative. Twenty-four-hour urinary LH 2 iu, FSH 1.5 iu. Karyotype: normal female. Adrenal function on Day 9 (soluble Synacthen 0.25 mg i.m.): plasma cortisol at 0 min, 1.52 tkmol/l; at 30 min, 1.56 ,umol/l; at 60 min, 1.38 ,umol/l (all grossly elevated). On Day 11 (insulin 0.1 u/kg i.v.): no rise in plasma cortisol or serum growth hormone (minimum blood sugar 0.5 mmol/l). Thyroid status: Serum T4 56 nmol/l (normal 60-150), Thyopac-4 126% (normal 95-119), free thyroxine index 0.44 (normal 0.60-1.50), serum T3 0.3 nmol/l (normal 1.2-2.8). Thyroid microsomal and thyroglobulin antibodies negative. Serum cholesterol 5.1 mmol/l (normal 4.0-7.5). TRH rest (200 , tg i.v.) : at 0 min 7.0 mu/I; at 10 min, 15.6; at 20 min, 17.0; at 40 min, 18.1; at 60 min, 29.4 mu/I. Follow up: A marked physical and mental improvement was made on thyroxine and prednisone replacement therapy. Six months later she permitted further investigations, previously refused, which disclosed: significant rise in neck uptake of 1311 following bovine TSH; a paradoxical fall in FSH and LH after LHRH (basal FSH 5.3 u/I; LH 3.6 u/I). At a later date an EMI scan of her skull was normal. Comment A number of unusual features were present in this case. The florid psychosis seemed to have a metabolic basis related to initial hypopituitarism with adrenal and thyroid insufficiency and water intoxication and then rapidly changing biochemical status with correction of hypo-osmolality and rapid rise in plasma cortisol to elevated levels. Psychosis in hypopituitarism has been previously described (Blau & Hinton 1960 ). In addition it seemed likely that there was an underlying schizoid personality.
The etiology of the pituitary failure also remains unclear. A pituitary tumour was effectively excluded radiologically and by EMI scanning. Hypothalamic dysfunction is a possibility, manifesting initially with primary amenorrhoea, yet permitting, or arising after, full skeletal development.
The TRH test showed a continued rise in plasma TSH for 60 minutes, suggesting a possible pituitary or hypothalamic disorder. In some such cases a high basal level of immunoreactive TSH has been reported (Patel & Burger 1973 , Faglia et al. 1973 . It was considered that this might reflect the secretion of biologically inactive TSH and so the samples from the TRH test were re-assayed using the sensitive cytochemical bioassay (CBA) (Mr V Petersen). The results displayed an atypical discrepancy from the radioimmunoassay (RIA) results: Liver function tests and liver scan were normal. Barium meal and follow through and jejuhal biopsy normal. Fasting plasma glucagon was 1268 pmol/l (normal 10), serum insulin 5 ,uu/ml. Plasma pancreatic peptide concentrations were in the normal range. Further investigations showed a rise in glucagon levels following the intravenous infusion of arginine (Fig 1) and tolbutamide (Fig 2) . When a bolus of glucagon (1 mg) was injected intravenously the blood glucose levels remained unaltered. Coeliac axis angiography demonstrated a large pancreatic tumour. Operation: Splenectomy and distal pancreatectomy. A 5 x 4 cm firm irregular mobile tumour was found in the tail of the pancreas close to the hilum of the spleen. There were multiple small metastases.
Histology: A well differentiated endocrine tumour showing positive immunofluorescence for glucagon.
Postoperative course: Uneventful recovery but still has fasting hyperglycemia. Plasma glucagon 140 pmol/l a week and 3 months after operation.
Discussion
Glucagonomas are rare and although a few reports are found in the literature (Table 1) only 5 fully documented cases have been described (McGavran et al. 1966 , Mallinson et al. 1974 ). Overproduction of glucagon is associated with a symptom complex consisting of dermopathy, mild diabetes, anemia, glossitis and occasionally diarrhoea. This patient fulfils all the criteria for the diagnosis of a glucagonoma. (Croughs 1974) : he had the classical features, a high plasma level of glucagon, a tissue diagnosis supported by the identification of glucagon secreting granules on electron microscopy and the tumour reacted only to pancreatic glucagon antibodies. Glucagonomas are far commoner in females than in males, although 3 cases have been reported in males (Grossner & Korting 1960 , Unger et al. 1963 , Mallinson et al. 1974 ). However, the patient described represents the first fully documented case of glucagonoma in a male. He is also the youngest patient reported apart from a woman who was diagnosed at 26 years of age (Yoshinga etal. 1966 ).
This man was labelled as a diabetic when he first presented but his glucose tolerance tests were always only marginally abnormal. The anmmia, glossitis and skin rash were intermittent, making diagnosis more elusive. During a period of three weeks when he was under close observation in hospital these features appeared to improve spontaneously; in retrospect this improvement coincided with withdrawal of sulphonylurea therapy and may be related to the marked release of glucagon provoked by these drugs (Fig 2) . Diarrhoea has been reported in some patients with glucagonoma (Mallinson et al. 1974) but constipation, which this patient suffered from, is more in keeping with the known physiological action of glucagon (Lefebvre & Unger 1972) .
Knowledge is limited about the prognosis for patients with glucagonoma. A history spanning 2-10 years before diagnosis was the rule in the series of Mallinson et al. (1974) , suggesting that glucagonomas may be slow growing. In the original report of the glucagonoma syndrome McGavran et al. (1966) noted that their patient was alive two and a half years after the recognition of metastatic lesions and that no chemotherapy had been used. As regards response to chemotherapy, the only guidance is derived from reports of 4 patients with malignant islet cell tumours producing multiple hormones including glucagon (Murray-Lyon et al. 1968 , Border & Carter 1973 ). Following treatment with streptozotocin, glucagon levels returned to normal in 2 of these patients whilst the rest did not respond. As streptozotocin does not affect the a-cells in animals given doses toxic to ,8-cells (Rakieten et al. 1963 , Junod et al. 1967 it is an initially unpromising agent for the treatment of glucagonomas. Lightman & Bloom (1974) reported that, in a patient who had required insulin previously, resection of a malignant glucagonoma without metastases led to a return to normal glucose tolerance. In our case, although following resection of the primary lesion the plasma glucagon fell, the presence of metastases accounts for persistently high levels. In spite of the very high plasma glucagon in this patient, his diabetes has been mild throughout and at present, with dietary carbohydrate restriction alone, he has normal postprandial blood sugars. This suggests that elevated glucagon levels are no more likely to be important in the etiology of diabetes than other known diabetogenic hormones such as cortisol or growth hormone. It is interesting to note that in spite of attempts to connect glucagon with developinent of ketoacidosis in diabetes mellitus (Gerich et al. 1975) , neither this patient nor any of the other glucagonoma patients described developed ketoacidosis.
